Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Literature DB >> 30393623

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Alfredo Addeo¹, Giuseppe Luigi Banna².

Abstract

Entities: Disease

Year: 2018 PMID： 30393623 PMCID： PMC6193909 DOI： 10.21037/tlcr.2018.07.10

Source DB: PubMed Journal: Transl Lung Cancer Res ISSN： 2218-6751

× No keyword cloud information.

21 in total

1. How to develop novel treatments for EGFR-mutant lung cancer.

Authors: Giuseppe Luigi Banna; Marcello Tiseo
Journal: Future Oncol Date: 2015-08-13 Impact factor: 3.404

2. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors: Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal: Cancer Discov Date: 2013-09-27 Impact factor: 39.397

3. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Authors: Zhong-Yi Dong; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Zhi Xie; Si-Yang Liu; Hai-Yan Tu; Hua-Jun Chen; Yue-Li Sun; Qing Zhou; Jin-Ji Yang; Xue-Ning Yang; Jia-Xin Lin; Hong-Hong Yan; Hao-Ran Zhai; Li-Xu Yan; Ri-Qiang Liao; Si-Pei Wu; Yi-Long Wu
Journal: Clin Cancer Res Date: 2016-12-30 Impact factor: 12.531

4. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Authors: Sara Pilotto; Antonio Rossi; Tiziana Vavalà; Alessandro Follador; Marcello Tiseo; Domenico Galetta; Alessandro Morabito; Massimo Di Maio; Olga Martelli; Orazio Caffo; Pier Luigi Piovano; Diego Cortinovis; Nicoletta Zilembo; Clelia Casartelli; Giuseppe Luigi Banna; Antonio Ardizzoia; Maria Luisa Barzelloni; Alessandra Bearz; Giovenzio Genestreti; Claudia Mucciarini; Virginio Filipazzi; Jessica Menis; Elisa Rizzo; Fausto Barbieri; Erika Rijavec; Fabiana Cecere; Gianluca Spitaleri; Emilio Bria; Silvia Novello
Journal: Clin Lung Cancer Date: 2017-06-01 Impact factor: 4.785

5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

Review 6. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.

Authors: Alfredo Addeo; Fabrizio Tabbò; Tim Robinson; Lucio Buffoni; Silvia Novello
Journal: Crit Rev Oncol Hematol Date: 2017-12-30 Impact factor: 6.312

Review 7. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

Authors: Barbara Melosky; Quincy Chu; Rosalyn Juergens; Natasha Leighl; Deanna McLeod; Vera Hirsh
Journal: J Clin Oncol Date: 2016-02-16 Impact factor: 44.544

8. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors: Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal: Clin Cancer Res Date: 2016-05-25 Impact factor: 12.531

9. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Authors: K Haratani; H Hayashi; T Tanaka; H Kaneda; Y Togashi; K Sakai; K Hayashi; S Tomida; Y Chiba; K Yonesaka; Y Nonagase; T Takahama; J Tanizaki; K Tanaka; T Yoshida; K Tanimura; M Takeda; H Yoshioka; T Ishida; T Mitsudomi; K Nishio; K Nakagawa
Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976

Review 10. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.

Authors: Jung Han Kim; Hyeong Su Kim; Bum Jun Kim
Journal: Oncotarget Date: 2017-07-18

1 in total

Review 1. Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.

Authors: Alex Friedlaender; Giuseppe Banna; Sandip Patel; Alfredo Addeo
Journal: Curr Treat Options Oncol Date: 2019-09-04

1 in total